EADV 2026: Real-World Outcomes with Sonidegib and Cemiplimab in Advanced Cutaneous Carcinomas
How do sonidegib and cemiplimab perform in real-world clinical practice? Dr. Chiara Del Re, dermatologist at Magna Graecia University in Italy, shares findings from a single-center observational study, exploring efficacy, lesion reduction, and safety in patients with advanced cutaneous carcinomas presented at EADV 2026.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
